Multicentric Castleman Disease (MCD) Latest Advances

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

Journal: Renal failure

Published: June 18, 2026

A Rare Case of Fabry Disease Combined With Idiopathic Multicentric Castleman Disease and Membranous Nephropathy.

Journal: Kidney medicine

Published: June 15, 2026

Idiopathic Multicentric Castleman Disease Presenting as Recurrent Acute-Onset Demyelinating Neuropathy.

Journal: Internal medicine (Tokyo, Japan)

Published: May 31, 2026

Correction to: Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective.

Journal: American journal of clinical pathology

Published: May 26, 2026

Multicentric Castleman Disease Initially Diagnosed as Disseminated Tuberculosis in an Adolescent Boy in Sokoto, Nigeria.

Journal: West African journal of medicine

Published: May 24, 2026

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: May 15, 2026

CRE26-069: Human Herpesvirus-8 Associated Multicentric Castleman Disease Presenting as Secondary Hemophagocytic Lymphohistiocytosis in Human Immunodeficiency Virus Infection.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

Sustained Remission of More Than 5 Years After Thalidomide-Cyclophosphamide-Prednisone Discontinuation in Idiopathic Multicentric Castleman Disease: A Single-Centre Retrospective Study.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: April 27, 2026

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Journal: BMJ case reports

Published: April 21, 2026

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

Journal: American journal of hematology

Published: April 18, 2026

A Case of TAFRO (Thrombocytopenia, Anasarca, Fever or Fibrosis of the Bone Marrow, Renal Dysfunction, and Organomegaly): Exploring the Idiopathic Variant of Multicentric Castleman Disease.

Journal: Cureus

Published: April 16, 2026

Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.

Journal: Drug discoveries & therapeutics

Published: April 01, 2026

Multicentric Castleman Disease (MCD) Latest Advances

Find the Latest Research About Multicentric Castleman Disease (MCD)

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.

A Rare Case of Fabry Disease Combined With Idiopathic Multicentric Castleman Disease and Membranous Nephropathy.

A Rare Case of Fabry Disease Combined With Idiopathic Multicentric Castleman Disease and Membranous Nephropathy.

Idiopathic Multicentric Castleman Disease Presenting as Recurrent Acute-Onset Demyelinating Neuropathy.

Idiopathic Multicentric Castleman Disease Presenting as Recurrent Acute-Onset Demyelinating Neuropathy.

Correction to: Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective.

Correction to: Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective.

Multicentric Castleman Disease Initially Diagnosed as Disseminated Tuberculosis in an Adolescent Boy in Sokoto, Nigeria.

Multicentric Castleman Disease Initially Diagnosed as Disseminated Tuberculosis in an Adolescent Boy in Sokoto, Nigeria.

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

Intensive Administration of Siltuximab Monotherapy for Idiopathic Multicentric Castleman Disease-TAFRO Subtype:Report of One Case.

CRE26-069: Human Herpesvirus-8 Associated Multicentric Castleman Disease Presenting as Secondary Hemophagocytic Lymphohistiocytosis in Human Immunodeficiency Virus Infection.

CRE26-069: Human Herpesvirus-8 Associated Multicentric Castleman Disease Presenting as Secondary Hemophagocytic Lymphohistiocytosis in Human Immunodeficiency Virus Infection.

Sustained Remission of More Than 5 Years After Thalidomide-Cyclophosphamide-Prednisone Discontinuation in Idiopathic Multicentric Castleman Disease: A Single-Centre Retrospective Study.

Sustained Remission of More Than 5 Years After Thalidomide-Cyclophosphamide-Prednisone Discontinuation in Idiopathic Multicentric Castleman Disease: A Single-Centre Retrospective Study.

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Idiopathic multicentric Castleman disease in a patient with an IgG4-related disease phenotype.

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease.

A Case of TAFRO (Thrombocytopenia, Anasarca, Fever or Fibrosis of the Bone Marrow, Renal Dysfunction, and Organomegaly): Exploring the Idiopathic Variant of Multicentric Castleman Disease.

A Case of TAFRO (Thrombocytopenia, Anasarca, Fever or Fibrosis of the Bone Marrow, Renal Dysfunction, and Organomegaly): Exploring the Idiopathic Variant of Multicentric Castleman Disease.

Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.

Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.